focus -WSS

focus

author：explore 2025-09-29 23:28:10 - browse：3956

Portrait of R. Shawn Martin -- health coverage from STAT — R. Shawn Martin, the CEO of the American Academy of Family Physicians Courtesy American Academy of Family Physicians

In ten years, the United States could be short as many as 48,000 primary care doctors. The specialty is underpaid, to a point that doctors are lobbying Medicare to pay it extra. Even medical residents who chose the specialty are leaving primary care; some 45% of residents who planned to be generalists changed their mind during their residencies.

But R. Shawn Martin, the CEO of the American Academy of Family Physicians, the specialty trade group, isn’t worried.

“I’ve been around this and at this a long time and family medicine and primary care’s obituary has been written many times in my 25-plus years of doing this work,” he said with a laugh. “This isn’t the first time that primary care has been dying or fading away.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Lasker Awards 2023: Winners in biomedical research

focus

WSS

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

FDA panel to weigh approval of NurOwn, controversial ALS drug

'Little Tech' descents on D.C., wanting a say in how AI is regulated

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Microbiome research is starting to find links to chronic diseases

How Vertex's cystic fibrosis drug is changing patients' lives

Wikipedia

focus

explore

Cancer drug shortages should be causing more outrage

Second xenotransplant done with gene

Sports medicine is finally prioritizing gender equality

CDC's new outbreak response network to include Northeastern

Medical leaders decry Supreme Court decision on affirmative action

Ukraine and a new approach to mental health in war

As demand for Covid shots wanes, Moderna seeks its next success

Sutter Health’s antitrust win overturned by appeals court

Apple is now the first public company to be valued at $3 trillion

What Congress can do to address the rural doctor shortage

focus

FDA panel to weigh approval of NurOwn, controversial ALS drug

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Biotech lab space demand falls sharply

EpiPen alternative approval delay highlights citizen petition issue

'Little Tech' descents on D.C., wanting a say in how AI is regulated

'Little Tech' descents on D.C., wanting a say in how AI is regulated

hotspot

focus

focus

focus